XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Notes Payable (Details) - BioLite Taiwan [Member] - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Notes Payable (Textual)          
Interest expenses   $ 3,014 $ 2,907 $ 6,002 $ 5,814
Unsecured loan agreements, description Entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $102,000, for working capital purpose.        
Balance due amount   $ 102,000 $ 100,200 $ 102,000 $ 100,200
Description of total consideration       The total consideration for obtaining such grant was NT$17,000,000 (equivalent approximately $573,500), of which NT$3,400,000 (equivalent approximately $114,710) is due within 30 days upon signing the agreement and the remaining balance of NT$13,600,000 (equivalent approximately $458,000) is due pursuant to a milestone payment schedule. In addition, the Company is required to pay PITDC 10% of sublicensing revenues net of related research and development cost and royalties at a range from 1% to 3% of sales of drugs. The Company paid the upfront payment of NT$3,400,000 (equivalent approximately $114,710) in 2011, the first milestone payment of NT$2,550,000 (equivalent approximately $86,000) in 2012, and the third milestone payment of NT$2,125,000 (equivalent approximately $71,700) in 2013. The Company recorded these amounts as research and development expenses when incurred. Pursuant to the in-licensing collaboration agreement with PITDC, the Company is required to pay PITDC 10% of sublicensing revenues to PITDC. On April 30, 2020, the Company recorded notes payable to PITDC for the fourth milestone payment of NT$1,338,750 (equivalent to $45,518). As of June 30, 2020 and December 31, 2019, the accrued milestone payment was $45,518 and $0, respectively.